Wegovy Dosing Explained: How High of a Dose Does Wegovy Go To?

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in injectable weight loss medications, works through a step-up dosing protocol that typically spans 16 to 20 weeks before reaching maintenance levels. This gradual approach allows your body to adapt to the medication while your provider monitors tolerability and effectiveness. PlexusDx delivers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with your dose adjusted as needed—your price remains flat regardless of escalation.

Understanding Semaglutide Dose Levels and Escalation

Semaglutide injections begin at a low starting dose, typically 0.25 mg once weekly, and increase incrementally over several months. Each dose escalation happens approximately every four weeks, moving through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the standard maintenance dose. This titration schedule allows your GLP-1 receptors to become increasingly sensitive to the medication while your gastrointestinal system adjusts to its appetite-suppressing effects.

The maximum approved maintenance dose for semaglutide injectable therapy is 2.4 mg weekly in most clinical settings. Some patients may experience adequate weight loss response at intermediate doses like 1.7 mg and choose to remain at that level rather than advancing further. Your PlexusDx provider evaluates your individual response, side effect tolerance, and weight loss progress to determine the optimal dose for your body.

Why Slow Titration Reduces Nausea and Side Effects

Rapid dose increases cause gastrointestinal side effects including nausea, vomiting, and constipation in a significant portion of patients. The slow four-week escalation interval gives your body time to adapt to semaglutide's mechanism, which slows gastric emptying and increases feelings of fullness. Research shows that patients who follow the standard titration schedule report fewer medication-related side effects and better long-term adherence compared to those receiving faster dose increases.

Nausea typically peaks within the first 1-2 weeks after a dose increase and naturally diminishes as your system adjusts. Staying at each dose level for the full four-week period allows this adaptation window to occur before moving higher. PlexusDx providers monitor your tolerability at each stage and can extend the interval between dose increases or hold at a current dose if side effects remain significant.

Maintenance Dosing and Long-Term Weight Loss Results

Once you reach the 2.4 mg weekly maintenance dose, most patients remain at that level indefinitely as long as their weight loss goal is being achieved and side effects remain manageable. Clinical trials show that patients at the 2.4 mg dose experience approximately 15% to 22% body weight reduction over 68 weeks compared to placebo. This sustained effect reflects semaglutide's ongoing impact on hunger hormones, appetite regulation, and metabolic rate.

Some patients notice a plateau in weight loss after several months at maintenance dose, which is a normal biological response. At this point, your PlexusDx provider may recommend continuing the same dose, exploring complementary lifestyle strategies, or in select cases, discussing dual-compound options. The goal is finding the dose level that delivers meaningful weight loss while keeping side effects minimal and sustainable.

Personalized Dosing with PlexusDx Precision Peptide Genetic Testing

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Patients with certain GLP1R genetic variants may achieve excellent results at lower maintenance doses like 1.7 mg, while others with different MC4R or FTO variants may benefit from reaching the full 2.4 mg dose. Genetic insights help your provider avoid unnecessary dose escalations and tailor your treatment timeline to your pathway-level genetic baseline. PlexusDx combines this genetic data with your clinical progress to create a truly personalized semaglutide protocol.

Cost Transparency: Your Dose Goes Up, Your Price Stays the Same

PlexusDx charges a flat monthly rate for compounded semaglutide injections regardless of which dose you're taking—whether you're starting at 0.25 mg or maintaining at 2.4 mg. Your price is $189/mo month-to-month, or from $149/mo on the 6-month plan and remains consistent across all three commitment tiers as your provider escalates your dose over the titration period. This pricing structure removes the financial barrier to reaching your optimal therapeutic dose.

Unlike some competitors who charge per-dose premiums, PlexusDx delivers all compounded medications from licensed 503A pharmacies with no hidden escalation fees. Your injections are HSA/FSA eligible, no insurance is required, and you can access treatment in all 50 states. This approach ensures that dose optimization is driven by your clinical needs rather than price concerns.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How long does it take to reach the maximum semaglutide dose?

Most patients reach the 2.4 mg maintenance dose after approximately 16 to 20 weeks of treatment, advancing one dose level every four weeks starting from 0.25 mg. Some individuals may need extended time at intermediate doses if side effects require a slower pace. Your PlexusDx provider tailors your titration timeline to your tolerability and response.

Can I skip a dose level if I tolerate semaglutide well?

Skipping dose escalations is not recommended because rapid increases significantly raise the risk of severe nausea and gastrointestinal side effects. Clinical guidelines emphasize the four-week interval at each level to allow physiologic adaptation. Your provider may adjust the timing slightly, but skipping levels typically results in worse tolerability outcomes.

Will I see weight loss results at lower semaglutide doses?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What happens if I cannot tolerate a higher semaglutide dose?

If nausea, vomiting, or other side effects become intolerable at a new dose level, your PlexusDx provider can hold your dose steady at the previous level indefinitely. Many patients achieve their weight loss goals at maintenance doses below 2.4 mg. In some cases, adjusting eating patterns, medication timing, or adding anti-nausea strategies can improve tolerability and allow further dose escalation.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

The PlexusDx Precision Peptide Genetic Test analyzes 49 peptides across 14 metabolic pathways, including MC4R variants that influence dose response sensitivity. This testing provides insights into your likely optimal dose range and predicted weight loss magnitude. Combined with your clinical progress, genetic data helps your provider make informed decisions about dose timing and target levels.

Why doesn't my semaglutide price increase when my dose goes up?

PlexusDx charges a flat monthly rate at $189/mo month-to-month, or from $149/mo on the 6-month plan for compounded semaglutide injections regardless of your dose level or number of escalations. This pricing approach removes financial barriers to reaching your optimal therapeutic dose. Your commitment to treatment is based on clinical benefit, not the cost burden of dose escalation.

Related Reading

• Wegovy For High Blood Pressure
• Ro Wegovy
• Mochi Wegovy
• Noom Wegovy

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.